Overview of Ibuprofeno Codramol

Quick Facts

Property	Description
Active ingredient	Ibuprofen
Form	Oral Solid Forms (e.g., tablet, capsule) or Oral Liquid Forms (e.g., suspension)
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
General Purpose	Symptomatic relief of pain, fever, and inflammation
Origin	Synthetic Compound

What Type of Medicine is Ibuprofeno Codramol?

Ibuprofeno Codramol is a pharmaceutical preparation whose identity is rooted in its definitive pharmacological class: a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification denotes a category of medications that manage symptoms of pain and inflammation through a non-steroidal pathway. The active ingredient is the internationally recognized substance Ibuprofen, which belongs to the subclass of propionic acid derivatives. The efficacy of Ibuprofen as an analgesic and antipyretic is clinically recognized worldwide, with extensive evidence supporting its role in the management of acute discomfort.

Composition and Origin of the Active Ingredient

The composition of Ibuprofeno Codramol centers on the sole component, Ibuprofen, which is a synthetic compound that was developed to ensure consistent purity and predictable action. The preparation is administered via the oral route, relying on pharmaceutical excipients to deliver the active substance effectively. The dosage forms commonly include oral solid forms (such as tablets or capsules) or, for certain patient groups like adolescents, oral liquid forms such as a suspension, which is often formulated with a specific flavor to improve acceptance.

General Therapeutic Purpose of Ibuprofen

The general purpose of this medicine is to help alleviate the symptomatic discomfort associated with the body’s inflammatory response, illness, or minor injury. Ibuprofen provides a triple therapeutic effect: it is an analgesic (pain reliever), an antipyretic (fever reducer), and a measurable anti-inflammatory agent (reducing swelling). This capability allows the product to offer temporary management for general conditions characterized by the concurrent presence of pain, an elevated body temperature, or localized swelling.

Regulatory References

Propionic Acid Derivative Classification

What side effects are possible with Ibuprofeno Codramol?

Safety Warnings and Adverse Reactions

Ibuprofeno Codramol is a combination product containing an NSAID (Ibuprofen) and an opioid analgesic (Codeine). The safety profile is defined by the known risks associated with both components, particularly when used long-term or at higher than recommended doses.

Serious Safety Concerns (Black Box Warnings)

Cardiovascular Thrombotic Events: Ibuprofen, as an NSAID, may increase the risk of serious, potentially fatal, cardiovascular thrombotic events, including Myocardial Infarction (heart attack) and Stroke. This risk may occur early in treatment and may increase with the duration of use and dose. This medication is generally contraindicated right before or after coronary artery bypass graft (CABG) surgery.
Gastrointestinal Events: NSAIDs carry a risk of serious, potentially fatal, adverse gastrointestinal events, including bleeding, ulceration, and perforation of the stomach or intestines. The risk is higher in the elderly and those with a history of GI disorders.
Opioid Risks (Codeine): The codeine component presents risks of dependence, abuse, and addiction, which can lead to life-threatening overdose. Repeated use may cause tolerance and physical dependence.

Organ-Specific and Metabolic Risks

Renal Damage: Prolonged use at higher-than-recommended doses has been associated with severe kidney damage, including renal tubular acidosis and hypokalaemia (low potassium levels). This is a particular concern in cases of dependence.
Allergic Reactions: Severe hypersensitivity reactions, including anaphylaxis, hives, and facial swelling, may occur, especially in individuals with known aspirin sensitivity.
Respiratory Depression: Codeine carries a risk of life-threatening respiratory depression.

Population-Specific Restrictions

Pregnancy: Use is advised against during the third trimester of pregnancy due to potential harm to the fetus and complications during delivery.
Pediatric Use: The use of codeine is restricted in children, and the product is generally not recommended for use in children under 12 years of age due to increased risks of serious side effects, including breathing problems. Use in breastfeeding mothers is generally not recommended.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency actions for overdose of Ibuprofen (the active ingredient in Ibuprofeno Codramol), based strictly on government regulatory documents.

Documented Clinical Manifestations

Overdose presentations typically include gastrointestinal symptoms (nausea, vomiting, epigastric pain, diarrhea) and CNS effects (drowsiness, lethargy, headache, tinnitus). Severe intoxications can lead to life-threatening systemic outcomes affecting major organs.

Severe Outcomes and Emergency Actions

Regulatory labeling specifies that overdose may be associated with severe CNS effects (convulsions, coma), cardiovascular instability (hypotension, bradycardia), and significant organ dysfunction, including acute renal failure and severe gastrointestinal hemorrhage. Due to these potential severe outcomes, regulatory authorities mandate that individuals seek immediate medical attention or contact a Poison Control Center following any suspected overdose.

Management and Monitoring

No specific antidote is known for Ibuprofen toxicity. Management is centered on symptomatic and supportive treatment. In a supervised setting, procedures such as the administration of activated charcoal may be considered. Continuous hospital monitoring of vital signs, electrolytes, and renal function is required for assessment and management of potential complications. Pediatric patients, especially if dehydrated, and geriatric patients have an increased risk for severe renal and gastrointestinal complications.

Therapeutic Uses of Ibuprofeno Codramol

Ibuprofeno Codramol is commonly used to provide supportive symptom management in conditions marked by heightened physiological stress. Its therapeutic role involves easing pain and reducing fever. The medication is relevant across domains where additional symptomatic support is needed, addressing symptoms related to physical discomfort and systemic imbalance manifested as fever.

It is commonly used to help with the management of mild to moderate pain, fever, and inflammation associated with conditions such as headache, dental pain, backache, menstrual cramps (primary dysmenorrhea), and musculoskeletal pain from sprains or common illness. Applied in clinical settings that involve acute or unstable symptom patterns, it assists with maintaining a sense of stability.

“The preparation supports patients during difficult episodes by easing distress.”

This approach is relevant when short-term symptomatic assistance is needed.

Quick Fact: Relief for Pain and Inflammation

Domain	Conditions/Symptoms Covered	Patient Benefit
Analgesia	Mild to moderate pain, tension headaches, dental pain.	Helps ease the overall symptom burden.
Antipyresis	Fever, elevated body temperature (e.g., cold/flu, post-vaccination).	Contributes to improved comfort during symptomatic periods.
Anti-Inflammatory	Swelling, joint tenderness, sprains, menstrual cramps.	Assists with maintaining a sense of stability.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use This Medicine

The following eligibility rules are strictly based on official government regulatory documents (e.g., FDA, EMA SmPC) and define the populations who may use this medicine and those who must not.

Populations That Must Not Use (Contraindicated)

Use is contraindicated (must not be used) in patients with a known allergy or hypersensitivity to ibuprofen, codeine, other non-steroidal anti-inflammatory drugs (NSAIDs), or any component of the medicine. It is also prohibited for individuals with an active, recurrent peptic ulcer or gastrointestinal bleeding/perforation or a history of bleeding related to prior NSAID therapy.

Furthermore, this medicine is contraindicated for those with severe organ failure (severe heart, liver, or kidney failure). Due to the codeine component, it must not be used by breastfeeding mothers, in the last trimester of pregnancy, or by patients who are known to be CYP2D6 ultra-rapid metabolisers.

Age and Restricted Use

This medicine is contraindicated for children under 12 years of age. Use is also prohibited in paediatric patients (0-18 years) after a tonsillectomy or adenoidectomy for obstructive sleep apnoea. Caution is advised for the elderly and for patients with mild-to-moderate organ impairment, a history of inflammatory bowel disease, or cardiovascular risk factors, where treatment requires careful consideration and the lowest effective dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile for Ibuprofeno Codramol is structured around documented risks and formal constraints associated with its Non-Steroidal Anti-Inflammatory Drug (NSAID) classification.

Interaction Severity	Interacting Product Categories	Official Interaction Outcome
Contraindicated	Other NSAIDs, High-dose Aspirin (>75 mg/day)	Prohibited due to the significant, documented risk of gastrointestinal bleeding and ulceration. Officially contraindicated for peri-operative pain after Coronary Artery Bypass Graft (CABG) surgery.
High-Risk/Exposure Modification	Oral Anticoagulants (Warfarin), Lithium, Methotrexate	Pharmacodynamic: Enhanced risk of bleeding, especially with Warfarin, Oral Corticosteroids, and Selective Serotonin Re-uptake Inhibitors (SSRIs). Pharmacokinetic: Reduced renal elimination is documented, leading to increased plasma concentrations of Lithium and Methotrexate.
Reduced Efficacy/Timing	Diuretics, Antihypertensives (ACE inhibitors, ARBs), Low-dose Aspirin	Ibuprofen may reduce the therapeutic effect of diuretics and certain antihypertensives. To avoid competitive inhibition of Aspirin’s antiplatelet action, regulatory guidance advises a timing separation: administer Ibuprofen 8 hours before or at least 2 to 4 hours after immediate-release low-dose Aspirin.

Interaction-Context Constraints

The use of alcohol, which is an independent risk factor for gastrointestinal bleeding, is officially noted to be exacerbated by co-administration with NSAIDs. Furthermore, the combination with diuretics or antihypertensives carries a population-specific note regarding an increased risk of nephrotoxicity, particularly in volume-depleted individuals. The profile also notes that some herbal products, such as Ginkgo biloba, may increase the risk of bleeding.

Mechanism of Action

Ibuprofeno Codramol achieves its physiological effects through the combined action of two components, each engaging a distinct pharmacodynamic domain: peripheral eicosanoid synthesis and central nociceptive signaling modulation. ### Prostaglandin Synthesis InhibitionThe ibuprofen component acts within the eicosanoid pathway to achieve non-selective, reversible inhibition of cyclooxygenase (COX) enzymes. By competitively blocking the active sites of both COX-1 and COX-2 isoforms, it impedes the conversion of arachidonic acid into prostanoids. This blockade of prostaglandin synthesis is the molecular mechanism by which ibuprofen modulates the intensity of pro-inflammatory signaling and alters the hypothalamic thermoregulation set-point.### Central Opioid Receptor EngagementThe second domain is mediated by the codeine component, which is metabolized to morphine in the liver. Morphine acts as an agonist primarily at the mu (mu) opioid receptors in the central nervous system (CNS), including sites in the spinal cord and brain. Engaging these G-protein coupled receptors initiates inhibitory neuronal signals, resulting in altered neurotransmitter release and modified signal transmission within descending nociceptive pathways. This central agonism supplements the peripheral effects on eicosanoid synthesis.

Dosage and Administration Information

How to Use Ibuprofeno Codramol: Official Administration Guidelines

The usage of Ibuprofeno Codramol (Ibuprofen) is governed by the principle of administering the lowest effective dose for the shortest duration necessary to manage symptoms. This medicine is administered exclusively via the oral route, utilizing dosage forms such as tablets, capsules, or oral suspension.

Administration Scope

Instruction Entity	Regulatory Guideline
Dosing Schedule	For acute symptomatic relief, the standard dose is 200 mg to 400 mg per administration. The non-prescription maximum total daily dose is 1200 mg, while the maximum limit under medical supervision is 3200 mg per 24 hours.
Frequency and Timing	Dosing should occur every 4 to 6 hours as needed, maintaining a required minimum interval of 4 hours between doses. For chronic, high-dose regimens, the total daily amount is administered in three or four equal divided doses.
Context of Intake	The medicine may be taken with food or milk to help mitigate potential gastric irritation. Conversely, administration on an empty stomach may be chosen for the fastest possible onset of action.
Preparation	Liquid forms, such as oral suspension, must be shaken well prior to administration. The dose must be accurately measured using a calibrated measuring device supplied with the product.
Duration of Use	Non-prescription use for pain should not exceed 10 days, and use for fever should not exceed 3 days, unless directed by a healthcare professional.

Procedural Structure

The official protocol requires the use of the appropriate strength (e.g., 200 mg or 400 mg) and form. Solid forms must be swallowed whole and should not be crushed or chewed, as this may alter the drug's intended absorption. Pediatric dosing for children under 12 years of age must be calculated based on body weight (mg/kg) according to the prescribing label. These instructions establish the standardized approach for using the medicine.

Recent Clinical Evidence

Evidence Base for Pain and Anti-inflammatory Use

Research for Ibuprofen is founded primarily on numerous short-term Randomized Controlled Trials (RCTs) and Systematic Reviews for acute physical discomfort. Studies examined outcomes such as pain intensity scores and the duration of observed symptom changes across diverse study populations, including adults and children over six months. Research has explored outcomes linked to inflammatory states, such as acute sprains, assessing localized pain and functional metrics. Findings describe patterns observed in these studies when compared against placebo or other compounds studied, including those related to very short-term pain following procedures like dental surgery.

Research on Primary Dysmenorrhea

Research specifically investigated symptoms associated with menstrual cramps (primary dysmenorrhea) using Randomized Controlled Trials. Studies examined outcomes such as measuring the severity of cramping and associated pain. Findings describe patterns observed in the studies regarding the reduction in pain scores over the symptomatic days of the menstrual cycle. Research so far indicates that the studies primarily focus on acute symptom changes; long-term outcomes regarding the condition itself are not comprehensively characterized.

Evidence Base for Fever Reduction (Antipyresis)

The antipyretic research base includes Comparative Trials focusing on studies related to elevated body temperature. Researchers measured the change in body temperature and the time required to achieve a predefined level of temperature change in populations ranging from infants (over three to six months) to adults. Findings describe patterns related to temperature change that are consistently observed in the study populations. Research is ongoing to further examine use parameters for the very youngest infant populations.

Evidence Landscape and Limitations

Studies in specific demographic groups, such as pediatric populations, adolescents, and older adults, are available, and the research describes that results apply only to the populations studied. Evidence for chronic condition management is less extensive, as most available data focuses on short-term or episodic symptom patterns. Long-term findings are not fully established, and Comparative evidence is lacking for some combinations and specific pain types, representing areas of ongoing research. Subgroup findings are uncertain for certain comorbidity groups where research is less extensive.

Key Studies & References

Non-steroidal anti-inflammatory drugs for acute low back pain

Frequently Asked Questions (FAQ)

Common questions about Ibuprofeno Codramol (FAQ)

Q: What is the main difference between Ibuprofeno Codramol and standard ibuprofen?

A: Official product information describes Ibuprofeno Codramol as a combination medicine. It contains the NSAID (Non-Steroidal Anti-Inflammatory Drug) Ibuprofen along with the opioid analgesic Codeine. Standard ibuprofen products contain only the NSAID component, making the presence of codeine the primary difference.

Q: How quickly does Ibuprofeno Codramol start to work?

A: According to the official product information, the medication typically begins to produce an effect within 30 to 60 minutes after administration. Official guidance notes that administration on an empty stomach may be associated with the fastest possible onset of action.

Q: How long can the effects of Ibuprofeno Codramol last?

A: Regulatory information indicates that the duration of action for the combined ingredients is approximately 4 to 6 hours. This duration corresponds to the recommended minimum interval between doses.

Q: Why are there warnings about stomach bleeding with Ibuprofeno Codramol?

A: Regulatory warnings emphasize that the Ibuprofen component, which is an NSAID, carries a serious risk of gastrointestinal bleeding, ulceration, and perforation. This effect is linked to how Ibuprofen works by inhibiting certain enzymes involved in protecting the stomach lining.

Q: Are there any common over-the-counter medicines that interact with Ibuprofeno Codramol?

A: Regulatory warnings specifically advise against taking other NSAIDs, such as non-prescription ibuprofen, naproxen, or aspirin (other than low-dose aspirin taken for heart protection). Using multiple NSAIDs simultaneously significantly increases the risk of stomach bleeding.

Q: Does Ibuprofeno Codramol interact with alcohol?

A: Regulatory labeling states that the risk of stomach bleeding is increased if three or more alcoholic drinks are consumed daily while using this product. The consumption of alcohol is noted to increase the gastrointestinal risk associated with the NSAID component.

Q: What are the signs of a serious allergic reaction to Ibuprofeno Codramol?

A: Official documentation warns of serious hypersensitivity reactions, which are considered serious adverse reactions. Signs can include symptoms such such as anaphylaxis (a severe reaction), hives, and facial or throat swelling.

Q: What should I know about drug tolerance developing with Ibuprofeno Codramol?

A: Regulatory information notes that repeated, regular use of the Codeine component over a long time may cause the body to develop tolerance. Tolerance is when the body gets used to the drug, meaning that a higher dose may be needed to achieve the same effect.

Q: Is it true that Ibuprofeno Codramol may have an effect on blood thinning?

A: Regulatory warnings state that the Ibuprofen component may interfere with the antiplatelet effect of low-dose aspirin. It may also enhance the risk of bleeding when taken with other medicines classified as blood-thinners.

Q: How does Ibuprofeno Codramol differ from pain relievers with only one active ingredient?

A: Official documents describe this product as having a dual mechanism of action. It combines the peripheral (body-wide) pain relief and anti-inflammatory effects of Ibuprofen with the central (nervous system) pain modulation of Codeine.

Q: What are the official guidelines regarding stopping the use of Ibuprofeno Codramol?

A: Regulatory documentation advises limiting non-prescription use to a short duration (typically 3 to 10 days). For prolonged or high-dose use, official warnings caution that abruptly stopping treatment can result in withdrawal effects related to the codeine component.

Q: Can Ibuprofeno Codramol be used for long-term pain management?

A: Official labeling for non-prescription use restricts the duration to a short period. For potential long-term use, regulatory warnings emphasize an increased risk of serious adverse events, including cardiovascular, gastrointestinal, and severe kidney damage.

Q: What types of pain is Ibuprofeno Codramol typically used for?

A: Official indications for use typically include the temporary relief of moderate to severe acute pain. This includes pain associated with strong headaches, migraine, dental procedures, menstrual cramps, and muscular aches.

Q: Is it normal to feel drowsy after taking Ibuprofeno Codramol?

A: Regulatory side effect profiles frequently list drowsiness or sleepiness as a possible effect of the medication. This effect is attributed to the presence of the codeine component, which acts on the central nervous system.

Q: Can older adults typically use Ibuprofeno Codramol?

A: Official guidelines advise that caution should be used when this medication is administered to the elderly population. This is because the risk of serious adverse events, particularly gastrointestinal bleeding, is generally higher in older adults.

Q: Is there any risk of becoming dependent on Ibuprofeno Codramol?

A: Official warnings state that the codeine component carries a risk of dependence, abuse, and addiction. This risk may exist even when the drug is used as directed by healthcare professionals.

Q: Can Ibuprofeno Codramol cause stomach upset even when taken with food?

A: Regulatory information suggests taking the medicine with food or milk to help mitigate or reduce the chance of gastric irritation. However, taking it with food does not remove all potential risk of stomach upset or adverse gastrointestinal events.

Q: Is Ibuprofeno Codramol suitable for people with asthma?

A: Official labeling generally contraindicates the use of this medicine in patients with aspirin-sensitive asthma. This warning applies to anyone with asthma or other acute breathing difficulties where NSAID use is known to be an issue.

Q: Can Ibuprofeno Codramol be split or crushed before taking?

A: Regulatory instructions for solid dosage forms require the medicine to be swallowed whole and not crushed or chewed. This is to ensure the intended rate and pattern of drug absorption are not altered.

Q: Does taking Ibuprofeno Codramol at night affect sleep?

A: Regulatory information notes that the drug’s components can cause central nervous system effects such as drowsiness or, conversely, difficulty sleeping. These effects are listed as possible adverse effects or potential withdrawal symptoms upon cessation.

Q: What evidence exists regarding the pain relief mechanism of the codramol component?

A: Official documents describe the codeine component as acting primarily as an agonist at the mu (mu) opioid receptors in the central nervous system. Engaging these receptors helps modify the transmission of pain signals in the brain and spinal cord.

Q: Are there documented cases of Ibuprofeno Codramol misuse or abuse?

A: Regulatory bodies have initiated formal reviews and changes in classification based on documented evidence of abuse and misuse of codeine-containing medicines. This evidence relates to products that combine ibuprofen with codeine.

Q: Are there specific populations for whom Ibuprofeno Codramol is not well-studied?

A: Regulatory summaries acknowledge that evidence for managing chronic conditions is less extensive than for acute conditions. They also state that subgroup findings are uncertain for certain comorbidity groups where comprehensive research is limited.

Q: Is Ibuprofeno Codramol the same as a prescription pain reliever?

A: The regulatory status of this medicine can vary significantly by country and formulation. Some strengths or forms are classified as prescription-only, while others may be available as over-the-counter (non-prescription) products.

Q: Can Ibuprofeno Codramol affect the results of certain medical tests?

A: Regulatory information indicates that the drug's metabolism is influenced by genetic factors related to the CYP2D6 enzyme, which can be relevant to certain tests. Additionally, the ibuprofen component may affect the results of tests measuring bleeding time.

How should Ibuprofeno Codramol be stored and disposed of?

How to Store and Dispose of Ibuprofeno Codramol?

This medication must be stored according to official regulatory requirements to ensure stability and safety, especially due to its codeine component.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store below 25 C or 30 C (check specific label); do not refrigerate or freeze.
Protection	Keep the medicine in the original packaging to protect it from light and moisture.
Child Safety	Keep out of the sight and reach of children to prevent accidental ingestion or misuse.

Disposal Instructions

Unused or expired Ibuprofeno Codramol must not be disposed of in household waste or flushed down the toilet. The product should be returned to a pharmacy or a designated drug take-back program following local pharmaceutical waste handling instructions as mandated by regulatory authorities.

Ibuprofeno Codramol